A 100 per cent tariff on imported pills

On 2 April the White House announced that the United States would impose a 100 per cent tariff on imported patented medicines and the ingredients that go into them, signed under the same Section 232 trade law that has been used to justify duties on steel and semiconductors. The framing was national security and public health, the bet being that a country which fills its medicine cabinets from factories on the other side of the world is, in an emergency, a country exposed.

The details are where the measure gets interesting. The headline rate is one hundred per cent ad valorem, but the proclamation is deliberately tiered. Companies that already make, or are assessed as likely soon to make, equivalent supply inside the United States can pay twenty per cent instead. The duties do not switch on immediately: large companies get a hundred and twenty days, smaller ones a hundred and eighty, a concession meant to give supply chains time to rearrange rather than seize. There are exemptions and review pathways written into the text, which is the standard architecture of a tariff that wants to look like leverage rather than a wall.

The logic inside the administration is not hard to follow. Over the last two decades, the manufacture of active pharmaceutical ingredients migrated offshore, above all to East Asia, because it was cheaper. The result is that even generic pills that cost pennies in rich countries often begin as a chemical intermediate made abroad. During the shocks of recent years, that dependence produced visible anxiety: a border disruption, a manufacturing halt, a price spike, and patients feel it at the pharmacy. A tariff is a way of pricing that dependence and, the theory goes, of persuading firms that it is cheaper to build a plant in Ohio than to pay the duty forever.

The costs are the mirror image of the benefits. A hundred per cent duty on a patented drug is, in the first instance, a price increase for the very patients the policy claims to protect. The carve-out for domestic builders helps, but a new factory takes years to break ground, and in the meantime the importers pay, and then bill. The Pharmaceutical Research and Manufacturers Association and importers’ lobbies were quick to point out that the measure will raise, not lower, the cost of care, and that the ingredients for many American-made pills are themselves imported. A duty designed to bring supply home could, in the short run, mainly make the existing supply more expensive.

There is also the trade-policy context. This is the latest in a long series of Section 232 tariffs, and it arrives in a year when courts have already scrutinized the legal reach of the president’s tariff powers. The pharmaceutical proclamation sits on the same legal foundation that judges have begun to question, so the measure’s durability is not assured even before the first invoice is charged.

What the bet amounts to is a familiar one in a new sector: use the border as a construction subsidy. The wager is that a punitive duty, phased in, will pull factories back across the Pacific faster than price signals would on their own. Whether that works depends on whether the lower twenty per cent rate and the long implementation window are enough to move a boardroom. Until the plants are built, the policy is a bet against its own immediate price effect.